Skip to main content

10-12-2019 | Haematology | Video

ASH 2019 | Triple drug combination with daratumumab shows promise in multiple myeloma

Saad Usmani highlights the phase 3 CANDOR trial findings demonstrating the survival benefits of adding daratumumab to carfilzomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma (4:18).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits